InFlectis BioScience, a pioneer in developing first-in-class therapies for neuromuscular diseases, announced that it has completed enrollment in its Phase 2
Nantes, France--(Newsfile Corp. - January 31, 2024) - InFlectis BioScience, a pioneer in developing first-in-class therapies for neuromuscular diseases, announced that it has completed enrollment in its Phase 2 clinical trial of IFB-088 (INN: icerguastat), a novel investigational treatment of Amyotrophic Lateral Sclerosis (ALS).
To view the full announcement, including downloadable images, bios, and more, click here.
Key Takeaways:
- InFlectis completed enrollment in its Phase 2 clinical trial of IFB-088 in ALS.
- IFB-088 is capable of crossing the blood-brain barrier and believed to act by selectively inhibiting a biomolecular switch to give cells additional time to repair or eliminate mis-folded proteins.
- Initial findings to be reported as early as the end of 2024.
Click image above to view full announcement.
About InFlectis BioScience
InFlectis is a French-based drug discovery company developing first-in-class therapies for neuromuscular diseases. We are in clinical development with an orally available small molecule that has the potential to extend lives or improve the quality-of-life for people suffering from ALS and CMT, a rare and progressive hereditary nerve condition.
Contacts:
Philippe Gu’edat
philippeguedat@inflectisbioscience.com
Source: Inflectis
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/196325
